QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases

Contributed by: Business Wire

Logo

Tags

Research

Neurology

Genetics

Biotechnology

Other Health

Health

Pharmaceutical

Other Science

Science

QurCan Therapeutics

More Like This

PR Newswire associated0

Tetra Pharm Technologies and Kvantify Announce Partnership to Accelerate the Discovery of Novel Drug Candidates Targeting the Endocannabinoid System

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies

Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

PR Newswire associated0

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology

Pandorum Technologies and Nucelion Therapeutics Announce Strategic Collaboration to Manufacture Exosome-Based Tissue Regenerative Therapy for Ocular Diseases in APAC Markets

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China